Trials / Recruiting
RecruitingNCT06016465
Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?
Does Nerve Block Plus Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hours Better Than Nerve Block Alone?
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Texas Tech University Health Sciences Center, El Paso · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard migraine treatment can reduce recurrence of headaches in the subsequent few days.
Detailed description
Previous studies have provided evidence that administering steroids in addition to standard migraine headache treatment in the emergency department may reduce the recurrence of the headache within 24-72 hours. The standard migraine treatments in previous studies have been varied and include 5-HT receptor agonists, dopamine antagonists, dihydroergotamine, NSAIDS, and opioid analgesics. The steroids added to the standard treatment have been prednisone and dexamethasone (both IV and oral). This is the first study to examine the combination of peripheral nerve block as the primary treatment of migraine followed by oral dexamethasone to prevent recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone Oral | Two 4mg pills |
| DRUG | Placebo | 2 placebo pills |
Timeline
- Start date
- 2023-09-15
- Primary completion
- 2025-12-30
- Completion
- 2026-01-30
- First posted
- 2023-08-29
- Last updated
- 2025-05-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06016465. Inclusion in this directory is not an endorsement.